Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Open Label, Multi-center, Dose Optimization and Dose Expansion Study to Assess the Safety and Efficacy of DFV890 in Adult Patients With Myeloid Diseases

NCT05552469 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT05552469
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05552469 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Open Label, Multi-center, Dose Optimization and Dose Expansion Study to Assess the Safety and Efficacy of DFV890 in Adult Patients With Myeloid Diseases
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 1
Overall status
Active, not recruiting
Start date
May 8, 2023
Completion date
February 1, 2027
Enrollment
71 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

myeloid diseases